CircFAM114A2 exerts a tumor suppressor role in HCC through miR-630/HHIP axis, and may be served as a potential diagnostic and therapeutic biomarker for HCC patients.
CircFAM114A2 inhibits the progression of hepatocellular carcinoma via miR-630/HHIP axis.